knowledge -WSS

knowledge

author：focus 2025-09-03 03:32:09 - browse：434

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

entertainment

WSS

Caribou posts encouraging results on off

Telehealth startups are trying to fill the menopause care vacuum

When a patient nears the end, a feared therapy can comfort

Burning questions for the 2024 JPM Healthcare Conference

Morgan Health, with ambitious aims, wants you to know it’s still here

Why psychiatrists like me stop taking insurance

Wikipedia

knowledge

focus

Wildfire smoke exposes gaps in outdoor worker protections

3 trends to watch in health tech's hiring outlook for 2024

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

JPM: CVS says Medicare Advantage patients are impacting profits

Jerome Adams on the need for new antivirals for Covid

In rare move, senator releases unverified FBI source report alleging Biden bribe

Medicare proposal to cover medical devices draws a mixed reaction

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Apple is now the first public company to be valued at $3 trillion

The FDA must approve intranasal treatments for anaphylaxis

focus

After a decade, new Gardasil ad campaign gets it (mostly) right

Judge denies Trump's request for new trial in E. Jean Carroll case

New weight loss drugs work. But how can they best be used?

There’s a way to spot data fakery. All journals should be using it

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Goldman Sachs launches $650M fund for life science investments

explore

leisure time

entertainment

leisure time